A new method for isolating and genome sequencing an individual malaria parasite cell has been developed by Texas Biomed researchers and their colleagues. This advance will allow scientists to improve their ability to identify the multiple types of malaria parasites infecting patients and lead to ways to best design drugs and vaccines to tackle this major global killer. Malaria remains the world’s deadliest parasitic disease, killing 655,000 people in 2010.
Malaria parasite infections are complex and often contain multiple different parasite genotypes and even different parasite species. So when researchers take a blood sample from a malaria infected patient, and look at the parasite DNA within they end up with a complex mixture that is difficult to interpret.
"This has really limited our understanding of malaria parasite biology" says Ian Cheeseman, Ph.D., who led this project. “It’s like trying to understand human genetics by making DNA from everyone in a village at once. The data is all jumbled up – what we really want is information from individuals.”
To achieve a better understanding of malaria parasites – single celled organisms that infect red blood cells – Cheeseman and colleague Shalini Nair, developed a novel method for isolating an individual parasite cell and sequencing its genome. These “single cell genomics” approaches have been adopted in cancer research to identify how tumors evolve during the progression of a disease but it has been difficult to adapt them to other organisms.
“One of the real challenges was learning how to cope with the tiny amounts of DNA involved. In a single cell we have a thousand million millionth of a gram of DNA. It took a lot of effort before we developed a method where we simply didn’t lose this,” said Nair, the first author on the work.
Their method is set to change how researchers think about infections. “One of the major surprises we found when we started looking at individual parasites instead of whole infections was the level of variation in drug resistance genes. The patterns we saw suggested that different parasites within a single malaria infection would react very differently to drug treatment” said Nair. “We’re now able to look at malaria infections with incredible detail. This will help us understand how to best design drugs and vaccines to tackle this major global killer,” Cheeseman added.
A paper describing this work, funded by the Texas Biomedical Forum, National Institutes of Health, a Cowles Postdoctoral Training Fellowship and the Wellcome Trust, was published online May 8 in the journal Genome Research. The work was led by Texas Biomed’s Cheeseman with collaborators at the University of Texas Health Science Center San Antonio, Case Western Reserve University, the Cleveland Clinic Lerner Research Institute, the Shoklo Malaria Research Unit, Thailand, and the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi. The other Texas Biomed author on is Tim Anderson, Ph.D.
This work was supported by a US National Institutes of Health grant No. R37AI048071.
Cheeseman can be reached through Jim Dublin at firstname.lastname@example.org or 210-227-0221.
Texas Biomed, formerly the Southwest Foundation for Biomedical Research, is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers, and parasitic diseases responsible for malaria, schistosomiasis and Chagas disease. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases. For more information on Texas Biomed, go to www.TxBiomed.org.